Drug Discovery World

APRIL 30, 2024

Reece Armstrong explores the potential and future opportunities for mRNA-based therapies. For instance, consider how at the end of 2018, the mRNA therapies market was valued at $3.43 mRNA-based approaches can produce proteins / peptides by using protein synthesis which is processed in a transfected cell 1.

Therapies 130

Therapies RNA Vaccine Small Molecule 130

Dark Matter Blog

JULY 16, 2021

My last stop at Arrakis Therapeutics is with a company targeting RNA with small molecules. I was enticed by Arrakis’ founder Jen Petter to serve in one more operational role, leading the research group at Arrakis as the company launched as one of the first biotechs to target RNA with drug-like small molecules.

Small Molecule 52

Small Molecule RNA Clinical Trials DNA 52

Drug Discovery World

JANUARY 12, 2023

Altering one base pair can drastically change how the gene’s protein product functions, while mutations can lead to the development of a range of genetic disorders. . The development of CRISPR has opened the door to ending diseases by fixing mutations and developing therapies through the process of modeling mutations.

Drugs 246

Drugs Disease Drug Development Therapies 246

Codon

MAY 30, 2023

This means that IscB base editors might be easier to package inside of AAVs, which can only store 4,700 bases of DNA for gene therapies. 3/ Cell Membrane Editor A cell is a lipid shell with lots of DNA, proteins, and RNA molecules inside. Molecular Therapy. Base editors made from Cas9 are about twice as big. Tech Crunch.

DNA 52

DNA RNA Engineering Vaccine 52

Codon

MAY 30, 2023

This means that IscB base editors might be easier to package inside of AAVs, which can only store 4,700 bases of DNA for gene therapies. 3/ Cell Membrane Editor A cell is a lipid shell with lots of DNA, proteins, and RNA molecules inside. Molecular Therapy. Base editors made from Cas9 are about twice as big. Tech Crunch.

DNA 52

DNA RNA Engineering Vaccine 52